2012 ARCC Conference
Canada’s 1st Applied Research Conference in Cancer Control
Monday May 28, 2012
Hilton Bonaventure Hotel
900 de la Gauchetiere W.
The objective of this conference was to bridge a connection between researchers and decision-makers, using health economics, services, policy and ethics research to improve cancer control and the delivery of cancer care.
Dr. David A. Henry, MB, ChB, MRCP, FRCP
David A. Henry is President and CEO of the Institute for Clinical Evaluative Sciences (ICES) in Toronto and Professor in the Department of Medicine at the University of Toronto, Canada. He is a physician with training in internal medicine, gastroenterology and clinical pharmacology. Currently, his interests include the use of controlled observational designs using linked population health data-sets to evaluate the benefits and harms of drugs, health systems performance, health services research and health technology evaluation. He has extensive experience of pharmaco-epidemiology and systematic review methodology. He has also worked in the field of pharmaco-economics and is the past chair of the Economics subcommittee of the Australian Pharmaceutical Benefits Advisory Committee. He was Director of the WHO Collaborating Centre for Training in Pharmacology and Rational Drug Use in Australia and still advises on the regulation and pricing of drugs in low and middle income countries.
Dr. Michael M. Burgess, Ph.D
Michael M. Burgess is Professor and Research Chair in Biomedical Ethics at the W. Maurice Young Centre for Applied Ethics in the Department of Medical Genetics at the University of British Columbia. His research has focused on health, science and technology policy and public engagement based on theories of deliberative democracy. With co-lead Kieran O’Doherty, the research team developed an approach to deliberative engagement on biotechnology policy, with eight events in BC, the Mayo Clinic and in western Australia across topics of biobanks, salmon genomics and environmental remediation. Recently, Dr. Burgess has begun to emphasize the wider social effects and policy implications of genomic and computational technologies often characterized as personalized medicine.
Dr. Carol Sawka, MD, FRCPC
Carol Sawka, is Vice President, Clinical Programs & Quality Initiatives and Co-Chair, Clinical Council, Cancer Care Ontario. In that role, she works with clinical leaders across the province to improve the quality and coordination of the full spectrum of cancer care. Dr. Sawka is a medical oncologist with a special interest in the management of breast cancer.
Dr. Sawka is a Professor in the Departments of Medicine, Public Health Sciences, and Health Policy, Management and Evaluation at the University of Toronto. Her research is focused on health services and policy research related to the cancer system.
Dr. Andrew Coldman, Ph.D
Andy Coldman is the Vice President of Population Oncology at the BC Cancer Agency. He has worked as a statistician/epidemiologist with the BC Cancer Agency since 1980 and holds joint-appointments as Adjunct Professor in the Departments of Statistics and Health Care and Epidemiology at the University of British Columbia. His research has focused on two principal areas. Firstly the measurement of the effectiveness of screening using population data modeling of screening processes and secondly the development and use of statistical indicators for use in cancer control measurement at the population level. In the last decade his research has concentrated on screening and he is currently a PI for the HPV Focal trial which is a randomized trial of HPV testing as a primary screening modality for cervical cancer. He continues to work in modeling cancer outcomes. Dr. Coldman is Chair of the technical subcommittee for the CPAC Risk Management Project and principal for the Collaborative stage implementation in the BC Cancer registry.
Peter Goodhand was appointed as the President and CEO of the Canadian Cancer Society on May 4, 2009. He originally joined the Canadian Cancer Society in 2004 as the Chief Executive Officer of the Society’s Ontario Division.
Mr. Goodhand sits on the board of Canadian Partnership Against Cancer, the Canadian Association of Provincial Cancer Agencies, the Governing Council of the Health Charities Coalition of Canada, the Advisory Committee on Oncology at Princess Margaret Hospital, the National Steering Committee of CIHR’s Strategy for Patient-Oriented Research and the Canadian Cancer Research Alliance’s Steering Committee for the Program to Support Clinical Trials Network. He is also the Chair of the Board of the Health Technology Exchange.
In 2009 Mr. Goodhand chaired the Government of Canada Expert Review Panel on the long-term future of medical Isotopes production. In 2011 he was a member of the official Canadian delegation to the UN High-Level Summit on Non-communicable Diseases.
Diane McArthur, MBA
Diane McArthur is Assistant Deputy Minister and Executive Officer of Ontario Public Drug Programs for the Province of Ontario. Prior to her appointment in June 2010, Diane was the Assistant Deputy Minister responsible for seniors’ issues within the Government of Ontario. Diane has held progressively more senior positions in several ministries since joining the Government of Ontario as a Management Intern in 1989. She has extensive experience in health human resource policy and planning for health provider training, education, supply and distribution initiatives, data and health information planning and analysis, health care provider negotiations, rural health policy, labour relations, and service delivery restructuring.
Dr. Mona Sabharwal, BScPhm, R.Ph
Mona Sabharwal is the inaugural executive director of the pan-Canadian Oncology Drug Review (pCODR). Ms. Sabharwal has worked in drug technology assessment and formulary management, in both British Columbia and Ontario, for more than 15 years. Before joining pCODR, she was the Senior Manager for Drug Programs Management with the Ontario Ministry of Health and Long-Term Care. In this role, she had operational oversight of the drug submission and evaluation process for Ontario’s seven public drug programs. Ms. Sabharwal was a key participant in the early development of pCODR and led operations for its precursor, the interim Joint Oncology Drug Review (iJODR). She was also instrumental in Ontario’s development of a new and innovative evaluation framework for Drugs for Rare Diseases, which was implemented in 2008. In 2010, she spear-headed and launched Ontario’s patient-evidence submission process, a formal process to systematically solicit patient-centred perspectives on new drug therapies.